Hoth Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HOTH research report →
About the company
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne.
- CEO
- Robb Knie
- IPO
- 2019
- Employees
- 6
- HQ
- New York, NY, US
Price Chart
- Market Cap
- $11.91M
- P/E
- -1.10
- P/S
- 0.00
- P/B
- 3.37
- EV/EBITDA
- -1.35
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -165.25%
- ROIC
- -277.16%
- Revenue
- $0 · 0.00%
- Net Income
- $-12,469,302 · -52.28%
- EPS
- $-0.90 · 29.69%
- Op Income
- $-11,110,849
- FCF YoY
- -40.49%
- 52W High
- $2.45
- 52W Low
- $0.49
- 50D MA
- $0.80
- 200D MA
- $1.11
- Beta
- 0.53
- Avg Volume
- 10.56M
Get TickerSpark's AI analysis on HOTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HOTH coverage
Recent articles, reports, and earnings notes.
No research on HOTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HOTH report →Similar companies
Peers in the same neighborhood.